Bulletin
Investor Alert

ZIOPHARM Oncology Inc.

NAS: ZIOP

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Oct 18, 2019, 6:59 p.m.

/zigman2/quotes/200291745/composite

$

4.06

Change

+0.12 +2.92%

Volume

Volume 15,893

Quotes are delayed by 20 min

/zigman2/quotes/200291745/composite

Previous close

$ 3.96

$ 3.95

Change

-0.02 -0.38%

Day low

Day high

$3.77

$3.98

Open

52 week low

52 week high

$1.56

$7.25

Open

Company Description

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the trea...

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of a diverse portfolio of cancer therapies. It focuses on developing products in immuno-oncology that employ novel gene expression, control, and cell technologies for the treatment of cancer. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

Valuation

P/E Current

-8.11

P/E Ratio (with extraordinary items)

4.31

Price to Sales Ratio

1,838.09

Price to Book Ratio

3.52

Enterprise Value to EBITDA

-11.77

Efficiency

Revenue/Employee

3,042.00

Income Per Employee

-1,106,604.00

Receivables Turnover

0.16

Total Asset Turnover

0.00

Liquidity

Current Ratio

8.89

Quick Ratio

8.89

Cash Ratio

6.51

Profitability

Operating Margin

-36,921.92

Pretax Margin

-36,381.51

Net Margin

-36,381.51

Return on Assets

-52.94

Return on Equity

-80.03

Return on Total Capital

-81.21

Return on Invested Capital

-80.03

Capital Structure

Officers and Executives

Name Age Officer Since Title
Dr. Laurence James Neil Cooper 54 2015 Chief Executive Officer & Director
Dr. David M. Mauney 50 2017 President
Mr. Satyavrat Shukla 47 2019 Chief Financial Officer & Executive Vice President
Ms. Lynn M. Ferrucci - 2012 SVP-IT, Human Resources & Administration
Dr. Eleanor M. de Groot - 2015 General Manager-Cell Therapy & Executive VP

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/07/2019 James Anthony Cannon
Director
15,000   Derivative/Non-derivative trans. at $0.7 per share. 10,500
01/06/2019 Laurence James Neil Cooper
Chief Executive Officer; Director
165,178   Derivative/Non-derivative trans. at $2.24 per share. 369,998
01/06/2019 Laurence James Neil Cooper
Chief Executive Officer; Director
446,428   Award at $0 per share. 0
01/06/2019 Laurence James Neil Cooper
Chief Executive Officer; Director
337,266   Award at $0 per share. 0
01/06/2019 David M. Mauney
President
159,010   Award at $0 per share. 0
01/06/2019 Robert Hadfield
General Counsel and Secretary
117,572   Award at $0 per share. 0
01/06/2019 Kevin G. Lafond
SVP, Treasurer & CAO
37,122   Award at $0 per share. 0
12/31/2018 Laurence James Neil Cooper
Chief Executive Officer; Director
16,156   Derivative/Non-derivative trans. at $1.87 per share. 30,211
12/31/2018 Kevin G. Lafond
SVP, Treasurer & CAO
9,334   Derivative/Non-derivative trans. at $1.87 per share. 17,454
12/31/2018 Elan Z. Ezickson
Director
80,214   Award at $0 per share. 0
12/31/2018 Douglas W. Pagán
Director
40,107   Award at $0 per share. 0
12/30/2018 Laurence James Neil Cooper
Chief Executive Officer; Director
26,178   Derivative/Non-derivative trans. at $1.66 per share. 43,455
12/30/2018 Kevin G. Lafond
SVP, Treasurer & CAO
13,100   Derivative/Non-derivative trans. at $1.66 per share. 21,746
12/29/2018 Laurence James Neil Cooper
Chief Executive Officer; Director
42,920   Derivative/Non-derivative trans. at $1.66 per share. 71,247
12/29/2018 James Anthony Cannon
Director
4,315   Derivative/Non-derivative trans. at $1.66 per share. 7,162
12/29/2018 Kevin G. Lafond
SVP, Treasurer & CAO
17,667   Derivative/Non-derivative trans. at $1.66 per share. 29,327
05/05/2018 Laurence James Neil Cooper
Chief Executive Officer; Director
123,333   Derivative/Non-derivative trans. at $4.41 per share. 543,898
12/31/2017 Laurence James Neil Cooper
Chief Executive Officer; Director
16,157   Derivative/Non-derivative trans. at $4.14 per share. 66,889
12/31/2017 Caesar J. Belbel
COO, CLO, and Secretary
21,667   Derivative/Non-derivative trans. at $4.14 per share. 89,701
12/31/2017 Francois Lebel
Executive Vice President R&D
21,667   Derivative/Non-derivative trans. at $4.14 per share. 89,701
12/31/2017 Kevin G. Lafond
SVP, Treasurer & CAO
9,333   Derivative/Non-derivative trans. at $4.14 per share. 38,638
12/30/2017 Laurence James Neil Cooper
Chief Executive Officer; Director
26,178   Derivative/Non-derivative trans. at $4.14 per share. 108,376
12/30/2017 James Anthony Cannon
Director
4,301   Derivative/Non-derivative trans. at $4.14 per share. 17,806
12/30/2017 Michael Weiser
Director
6,021   Derivative/Non-derivative trans. at $4.14 per share. 24,926
12/30/2017 Caesar J. Belbel
COO, CLO, and Secretary
31,450   Derivative/Non-derivative trans. at $4.14 per share. 130,203
12/30/2017 Francois Lebel
Executive Vice President R&D
31,450   Derivative/Non-derivative trans. at $4.14 per share. 130,203
12/30/2017 Wyche Fowler
Director
6,882   Derivative/Non-derivative trans. at $4.14 per share. 28,491
12/30/2017 Kevin G. Lafond
SVP, Treasurer & CAO
13,100   Derivative/Non-derivative trans. at $4.14 per share. 54,234
12/30/2017 Murray F. Brennan
Director
6,813   Derivative/Non-derivative trans. at $4.14 per share. 28,205
12/29/2017 Laurence James Neil Cooper
Chief Executive Officer; Director
348,000   Award at $0 per share. 0
12/29/2017 James Anthony Cannon
Director
17,258   Award at $0 per share. 0
12/29/2017 Michael Weiser
Director
17,258   Award at $0 per share. 0
12/29/2017 Caesar J. Belbel
COO, CLO, and Secretary
87,000   Award at $0 per share. 0
12/29/2017 Francois Lebel
Executive Vice President R&D
116,000   Award at $0 per share. 0
12/29/2017 Wyche Fowler
Director
17,258   Award at $0 per share. 0
12/29/2017 Kevin G. Lafond
SVP, Treasurer & CAO
53,000   Award at $0 per share. 0
12/29/2017 Murray F. Brennan
Director
17,258   Award at $0 per share. 0
12/12/2017 James Anthony Cannon
Director
13,094   Derivative/Non-derivative trans. at $4.17 per share. 54,601
12/12/2017 James Anthony Cannon
Director
20,000   Derivative/Non-derivative trans. at $2.73 per share. 54,600
/news/latest/company/us/ziop

MarketWatch News on ZIOP

  1. How to Make a Killing in Gene Therapy

    12:56 p.m. Sept. 18, 2018

    - Barron's Online

  2. Ziopharm Oncology says FDA has placed clnical hold on trial of leukemia treatment

    7:34 a.m. June 18, 2018

    - Ciara Linnane

  3. Ziopharm Oncology shares slide 7% premarket

    7:35 a.m. June 18, 2018

    - Ciara Linnane

  4. Ziopharm stock rallies 6% after company says no plans for stock offering

    1:05 p.m. Feb. 6, 2018

    - Emma Court

  5. Ziopharm Oncology upgraded to market perform from underperform at Wells Fargo

    9:57 a.m. Aug. 10, 2016

    - Tomi Kilgore

  6. Some Biotech Finally Hits Trough Valuations: Wells Fargo

    12:14 p.m. Jan. 21, 2016

    - Barrons Blogs

  7. Six stocks to watch

    3:13 p.m. Nov. 11, 2015

    - The Trading Deck

  8. Six ways to profit from Hillary Clinton’s $132 billion tweet

    10:03 a.m. Sept. 29, 2015

    - Michael Brush

  9. Soaring biotech stocks are looking a bit sickly

    6:01 a.m. April 1, 2015

    - Jeff Reeves

  10. 6 stocks to watch

    1:12 p.m. March 18, 2015

    - The Trading Deck

  11. 6 reasons biotech stocks may soon tank

    12:08 p.m. Feb. 26, 2015

    - Michael Brush

  12. Six stocks to watch

    4:13 p.m. Feb. 11, 2015

    - The Trading Deck

  13. Charting the Market

    10:41 a.m. Jan. 20, 2015

    - Barron's Online

  14. U.S. stocks end day with fourth-straight loss

    5:28 p.m. Jan. 14, 2015

    - Anora Mahmudova

  15. GameStop shares rally on strong holiday sales

    6:48 p.m. Jan. 13, 2015

    - Wallace Witkowski

  16. Loading more headlines...
/news/nonmarketwatch/company/us/ziop

Other News on ZIOP

  1. Ziopharm: 13 Failed Programs With 3 More On Deck

    1:37 p.m. Oct. 16, 2019

    - Seeking Alpha

  2. MNK, EXAS among premarket gainers

    9:10 a.m. Sept. 23, 2019

    - Seeking Alpha

  3. Apple, IPOs And German Auto (Stocks To Watch Podcast)

    7:03 a.m. Sept. 8, 2019

    - Seeking Alpha

  4. Stocks To Watch: Apple, IPOs And German Auto

    7:34 a.m. Sept. 7, 2019

    - Seeking Alpha

  5. Stephens sees 48% upside in Cerus in premarket analyst action

    7:17 a.m. Aug. 23, 2019

    - Seeking Alpha

  6. Most Heavily Shorted Stocks - August 2019

    10:00 a.m. Aug. 14, 2019

    - Seeking Alpha

  7. 10-Q: ZIOPHARM ONCOLOGY INC

    7:48 a.m. Aug. 8, 2019

    - Edgar Online - (EDG = 10Q, 10K)

  8. Week 31 Breakout Forecast: Short-Term Picks To Give You An Edge

    1:40 p.m. July 29, 2019

    - Seeking Alpha

  9. Biotechs' Second-Half Battle

    12:32 p.m. July 22, 2019

    - Seeking Alpha

  10. The Top 10 Best Sectors in the Market for 2019

    12:26 p.m. July 2, 2019

    - InvestorPlace.com

  11. The 7 Top Small-Cap Stocks Of 2019

    11:08 a.m. June 27, 2019

    - InvestorPlace.com

  12. Most Heavily Shorted Stocks - June 2019

    11:38 p.m. June 25, 2019

    - Seeking Alpha

  13. Ziopharm: Awakening The Sleeping Beauty CAR-T

    8:24 p.m. June 25, 2019

    - Seeking Alpha

  14. Biotech Stocks Getting Ready To Explode

    11:38 a.m. June 17, 2019

    - Seeking Alpha

  15. Loading more headlines...

At a Glance

ZIOPHARM Oncology, Inc.

Navy Yard Plaza

1 First Avenue

Parris Building 34, 3rd floor

Boston, Massachusetts 02129

Phone

1 6172591970

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2019

Revenue

$146,000

Net Income

$-53.12M

Employees

48.00

/news/pressrelease/company/us/ziop

Press Releases on ZIOP

  1. CAR-T Cell Therapy Market: Global Industry Analysis and Opportunity Assessment 2019-2025

    12:45 a.m. Sept. 14, 2019

    - Brandessence Market Research

  2. Loading more headlines...
Link to MarketWatch's Slice.